Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT07305025
Recruiting Not applicable

Pelvic Pain Electro-Acupuncture

NCT07305025 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2025-12-16
Last updated
2026-07-21

Condition(s) studied

Pelvic PainEndometriosis

Investigational drug(s) / intervention(s)

Electro acupuncture

Electro acupuncture: Frequency: 3 sessions per week for 3 weeks. Needle retention time: \~30 minutes per session. Electroacupuncture at a frequency of 2 Hz Electroacupuncture Stimulation Parameters Electroacupuncture will be administered at a frequency of 2 Hz, as this has been shown to stimulate the release of endogenous opioids, including endorphins and enkephalins. These neuropeptides contribute to pain modulation and inflammation reduction via activation of the body's natural analgesic pathways (7). Additionally, low-frequency stimulation at 2 Hz has been associated with parasympathetic nervous system activation, which may further enhance pain relief by reducing stress-related sympathetic activity and promoting a relaxed physiological state. This dual mechanism makes 2 Hz electroacupuncture a suitable intervention for chronic and inflammatory pain conditions. Electrode placement and treatment duration will be standardized across participants to ensure consistency in stimulation intensity, needle depth

Study summary

The aim of the study is to investigate if a series of up to 9 treatment sessions of electroacupuncture can be used to alleviate pain in women with suspected endometriosis, scheduled for diagnostic laparoscopy

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Women aged 18-45 years referred for diagnostic laparoscopy with suspicion of endometriosis * Experiencing moderate to severe pelvic pain * Willing to commit to the treatment schedule and follow-up * Understanding Norwegian or English to be able to communicate and fill out questionnaires Exclusion Criteria: * Pregnancy * Use of opioid pain relief * Concurrent participation in other pain management trials

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
St Olav's University Hospital Trondheim Norway Recruiting

More St. Olavs Hospital trials in Norway

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07305025 on ClinicalTrials.gov ↗ ← All trials in Norway